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INTRODUCTION
Spinocerebellar ataxia type 6 (SCA6), episodic ataxia type
2 (EA2) and familial hemiplegic migraine (FHM) have been
considered to be diverse disorders phenotypically as well as
genetically (1). 
SCA6, named by Zhuchenko et al. (1) is an autosomal
dominant disorder characterized by cerebellar functional
deficit and atrophy, which are slowly progressive and per-
manent. SCA6 is caused by CAG repeat expansions in the
CACNA1A gene on the short arm of the chromosome 19
(chromosome 19p) coding the  1Avoltage-dependent calci-
um channel subunit. The range of CAG repeats contained
at the 3′ end of the CACNA1A gene in SCA6 is from 21 to
27 (2-5). 
EA2 is inherited through an autosomal dominant pattern,
and manifests as intermittent cerebellar dysfunction, such as
attacks of vertigo, visual disturbance, dysarthria, and ataxia
lasting minutes to days. Nystagmus and other cerebellar signs
of variable severity are present during the interictal period
(6-8). Because EA2 responds to the acetazolamide, it is also
known as an acetazolamide-responsive/hereditary paroxysmal
cerebellar ataxia (APCA/HPCA) (9). It has been reported
that EA2 is caused by point mutations of the CACNA1A
gene on chromosome 19p. Point mutations produce trun-
cated proteins due to the disruption of the reading frame,
and these proteins cause abnormal  1A voltage-dependent
calcium channel subunits. 
In recent studies (10-12), both SCA6 and EA2 were con-
currently found in families with 26 CAG repeats without
any evidences for additional point mutations in either cod-
ing sequences or in intron-exon junctions or with one point
mutation without any abnormality of the CAG repeat num-
ber suggesting that SCA6 and EA2 are allelic disorders with
a high phenotypic variability. 
Here we report Korean family with SCA6 and EA2 and
with 26 CAG repeat allele without previously reported point
mutations.
CASE REPORT
The proband presented himself to us at the age of 49 yr
with a history of showing cerebellar ataxia and dysarthria
since the age of 41 yr.
He had experienced several attacks of vertigo and ataxia
lasting from minutes to hours in his early 40’ s. His episodic
symptoms were induced by stress or fatigue. He was treated
with dimenhydrinate (DramamineR) for the attacks. Over the
subsequent years, the episodic symptoms slowly progressed
in the frequency, severity, and duration. When he visited our
hospital, he had permanent cerebellar ataxia and dysarthria.
The neurological examination showed mild truncal atax-
ia, well-sustained jerky bilateral gaze-evoked and vertical
nystagmus during lateral gaze, dysarthric and mildly scan-
ning speech, bilateral dysmetria, mild bilateral decomposi-
tion, dysdiadochokinesia, falling tendency to either side on
the tandem gait, and swing both in eye-open and closure on
the Romberg test. For the initial treatment, 250 mg of aceta-
zolamide was given twice a day. Acetazolamide seemed to
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Spinocerebellar ataxia type 6 (SCA6), episodic ataxia type 2 (EA2) and familial
hemiplegic migraine (FHM) have been known as allelic disorders, which are
caused by the alteration of the  1A voltage-dependent calcium channel subunit.
Expansions of the CAG repeat in the CACNA1A gene on the short arm of the
chromosome 19 induce SCA6, and point mutations in the same gene are respon-
sible for EA2 and FHM. In recent studies, both SCA6 and EA2 have been con-
currently found in families with 26 CAG repeats without previously reported point
mutations either in coding sequences or in intron-exon junctions. We describe a
Korean family with CAG26 repeats in the CACNA1A gene. Some of the affected
family members had progressive ataxia typical of SCA6 whereas others had
episodic vertigo responsive to acetazolamide typical of EA2. Our family support
that SCA6 and EA2 are allelic disorders with a high phenotypic variability.
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be effective in the beginning, but the episodic symptoms had
slowly progressed. The 750 mg/day of acetazolamide was
ineffective for controlling central gaze-evoked and vertical
nystagmus and ataxia. 
The results of complete blood cell count, electrolyte anal-
ysis, simple chest radiograph, tumor markers ( FP, CEA,
CA19-9,  HCG, PSA, NSE), screening of intoxication of
several kinds of the heavy metals, and test for the connective
tissue disease were all in normal ranges. He had no history
of drug or alcohol abuse. 
The family history of the proband revealed 28 members
including 78-yr-old mother (II-1) and 76-yr-old maternal
aunt (II-2) who had been suffered from gait imbalance since
their late 40’ s, and 46-yr-old sister (III-3) and 50-yr-old cousin
(III-6) who had been suffered from gait imbalance, limb atax-
ia and dysarthria since their early 40’ s (Fig. 1, Table 1). 
In addition, his mother (II-1) often complained of inter-
mittent mild vertiginous sensation as well as interictal gait
imbalance mentioned above. She was maintained with 150
mg of dimenhydrinate for symptomatic relief. His 43-yr-
old brother (III-4) had experienced several attacks of vertigo,
dysarthria, and ataxia lasting minutes to hours and showed
mild interictal vertical nystagmus confirmed on neurologi-
cal examinations. These symptoms had come out at the age
of 39 yr. He has been taking daily 500 mg of acetazolamide,
which was effective.
Other family members in the next generation of the pro-
band’ s had no history of symptoms (Table 1). We per-
formed special radiological studies on the proband. The
brain MRI showed severe cerebellar atrophy, especially in
vermis (Fig. 2A), and brain SPECT decreased perfusion to
the cerebellum (Fig. 2B). 
The molecular genetic studies for spinocerebellar ataxia
type 1 (SCA1), type 3 (SCA3)/Machado-Joseph disease, and
SCA6 were done on the proband and his five family mem-
bers (III-1, III-3, III-4, III-5, IV-1, and IV-3). The results of
the test were negative for SCA1 and SCA3/Machado-Joseph
disease and positive for SCA6 in all subjects except one (III-
4). The molecular genetic study on the chromosome 19p
revealed that the number of the CAG repeat was 26. The
molecular genetic study for the diagnosis of SCA6 using the
II-1 F/78 45-50 Gait imbalance, intermittent 
vertiginous sensation
II-2 F/76 45-50 Gait imbalance, intermittent 
vertiginous sensation
III-1 M/49 40 Marked truncal and limb ataxia, 
(proband) nystagmus (gaze-evoked and 
downbeat nystagmus),
dysarthria and scanning speech
III-2 F/48 - Asymptomatic
III-3 F/46 41 Gait imbalance, limb ataxia and 
dysarthria
III-4 M/43 39 Several episodes of transient 
ataxia
III-5 M/40 - Asymptomatic
III-6 M/50 40 Limb ataxia, dysarthria and 
bilateral falling tendency
IV-1 F/24 - Asymptomatic
IV-2 F/22 - Asymptomatic
IV-3 M/20 - Asymptomatic
IV-4 M/18 - Asymptomatic
IV-5 F/16 - Asymptomatic
IV-6 F/14 - Asymptomatic
IV-7 M/13 - Asymptomatic
IV-8 F/11 - Asymptomatic
Number Symptoms and signs Sex/Age 
(yr)
Age of 
onset (yr)
Table 1. Clinical features of the proband and his family mem-
bers
II-1 Gait imbalance, intermittent 
vertiginous sensation 26
III-1 Marked truncal and limb ataxia, 
(proband) nystagmus (gaze-evoked and 
downbeat nystagmus), 26
dysarthria and scanning speech
III-3 Gait imbalance, 
limb ataxia and dysarthria 26
III-4 Several episodes of transient ataxia 26
III-5 Asymptomatic 12
IV-1 Asymptomatic 26
IV-2 Asymptomatic 26
IV-3 Asymptomatic 26
IV-4 Asymptomatic 13
IV-5 Asymptomatic 26
IV-6 Asymptomatic 26
IV-7 Asymptomatic 26
IV-8 Asymptomatic 26
Number Clinical features Number of CAG repeat
Table 2. Relation between clincal features and number of
CAG repeat
1 (EA2) 2 (maybe EA2)
6 
(maybe SCA6)
1 (SCA6) 5
12345 6 7 8
4 3 2
Phenotypically normal male
Symptomatic female
Phenotypically normal female
Proband
Symptomatic male
I
II
III
IV
Fig. 1. Pedigree of a Korean family with spinocerebellar ataxia
type 6. Roman numerals represent for the generation in chrono-
logical order and Arabic numerals for the respective individual
within the generation, e.g., III-1 for proband. The parenthesis
means phenotype. This designation for the family members is
also used in Table 1 and 2, and Fig. 3.
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Fig. 2. Image findings of the proband. A: Marked cerebellar
atrophy, especially in vermis, is observed in the brain MRI T2-
weighted image of axial view (A-I) and T1-weighted image of
sagittal view (A-II). B: Decreased perfusion in the cerebellum is
evident on the brain perfusion SPECT.
method of Zhuchenko et al. (1) was done on the six subjects
screen-ed and seven other family members (II-1, III-1, III-3,
III-4, III-5, IV-1, IV-2, IV-3, IV-4, IV-5, IV-6, IV-7, and IV-
8) and the result revealed that the number of the CAG repeat
was 26. 
Additional studies to confirm other possible point muta-
tions, which were already well known, were done and there
were no evidences for additional point mutations in these
subjects.
DISCUSSION
EA2 is characterized by episodes of ataxia lasting hours with
interictal nystagmus. SCA6 is classified autosomal dominant
cerebellar ataxia with CAG repeat expansion. 
Traditionally, the familial episodic ataxia has been classi-
fied separately from the hereditary spinocerebellar ataxia syn-
drome (13). Although the SCA6 and EA2 are the same allelic
disorders, the symptom of the SCA6 is a progressive ataxia,
rather than episodic ataxia as in EA2. However, progressive
symptoms are seen in EA2 patients linked to the chromo-
some 19p (8). In other words, EA2 patients are phenotypi-
cally diverse. There are at least four different clinical profiles
in EA2, i.e., basilar migraine-like attacks with minimal or
no interictal signs, episodes of ataxia with interictal nystag-
mus and mild progressive truncal ataxia, ill-defined episodes
of dizziness with progressive SCA, and hemiplegic migraine.
S812 S.-H. Koh, H.-T. Kim, S.-H. Kim, et al.
In addition to EA2, the phenotypic variability has been re-
ported on SCA6. According to the previous report, none of
the SCA6 patients showed episodic ataxia (3). But, it was
noted that SCA6 showed episodic exacerbations (4). Accord-
ing to a recent report (10, 11), SCA6 patients showed episod-
ic ataxia responsive to acetazolamide, and genetic studies
showed 22 CAG repeats. From a clinical standpoint the aver-
age age for the onset of SCA6 was about 40 yr and the pro-
gression of symptoms was slower in SCA6, whereas most of
the patients with EA2 began having episodes before the age
of 20 yr. 
However, the onset of progressive interictal ataxia was much
later in patients with EA2. It was suggested that the differ-
ences in the clinical phenotypes between SCA6 and EA2
probably reflect different genetic alterations, that is, CAG
repeat expansions in SCA6 versus point mutations in EA2
(1-5, 14). 
Zhuchenko et al. (1) reported that the age at disease onset
in SCA6 patients were 28-31 yr for 27 CAG repeats and 40-
50 yr for 22-23 CAG repeats, and that some patients with
EA, had much milder symptoms and smaller CAG repeats
than SCA6. Contrary to the report of Zhuchenko et al. (1),
the proband in this report had a CAG26 repeat expanded
allele and the age of onset was 41 yr. 
Geschwind et al. (4) and Jen et al. (11) reported SCA6 pa-
tients with typical EA2. These patients had the onset at the
age of 42 to 63 yr and the number of CAG repeat was 22.
Although the number of SCA6 patients with EA2 was too
small in these studies, these results seem to suggest that
there is no correlation between the number of CAG repeat
and the age of onset. The differences in genetic backgrounds
or environmental factors might explain the relatively later
onset of symptoms in our family compared to the findings
by Zhuchenko et al. (1)
In our study, the proband showed a central type of verti-
cal nystagmus induced by lateral gaze. The cerebellar lesion,
especially involving the flocculus, can cause vertical nystag-
mus and the patients with SCA6 had Purkinje cell loss on
autopsy (5, 14). In this report, the brain MRI showed severe
cerebellar atrophy, especially in vermis. The brain SPECT
revealed a deficit of cerebellar perfusion. Jodice et al. (10) re-
ported that patients with EA2 as well as SCA6 also had the
CAG expansion and cerebellar atrophy. The CAG expansion
affects the function of the calcium channel to trigger the
progressive neuronal loss by alteration of polyglutamine ex-
pansion causing abnormal level of intracellular Ca2+ leading
to cell death (15). The CAG repeat expansion of SCA6 occurs
in the coding region of a gene that is known to be impor-
tant for the normal function and the survival of Purkinje
cells (5).
Like ordinary EA2 patients, our patients reported episodes
of vertigo and ataxia precipitated by fatigue and stress. Such
episodes may result from transient impairments of the calci-
um channel triggered by environmental factors. According
to the previous reports (1, 8), FHM and EA2 are allelic dis-
orders that have been attributed to point mutations in the
same gene of CACNA1A on chromosome 19p. The gene
affected in SCA6 is similar with that in EA2 but the alter-
ation is CAG repeat expansion rather than a point mutation.
Jen et al. reported patients with SCA6 and with positional
vertigo and acetazolamide-responsive episodic ataxia (11).
In those patients, the causative genetic alteration was an 22
CAG repeats in CACNA1A, not a point mutation. It has
been suggested that a CAG repeat leads to progressive fea-
tures and a point mutation to purely episodic features. EA2
is clinically not benign, and progressive symptoms are often
seen in affected members of a kindred with typical chromo-
some 19p-linked EA2 (4, 8). 
In this report, we noted that EA2 with SCA6 could be
caused by a smaller size of CAG repeats (26 repeats) in the
CACNA1A calcium gene. EA2 and SCA6 are not only allel-
ic but also can have overlapping phenotypes. The mechanism
for this phenotypic variability or an overlapping syndrome
in families with EA2 and SCA6 linked to chromosome 19p
is unclear. But according to the present reports, the plausi-
ble mechanisms could be; 1) loss of function due to haploin-
sufficiency, 2) a dominant negative effect due to the expan-
sion or 3) a novel gain of function (10, 11). 
In the present time, the pathogenic effect of a CAG repeat
expansion with regard to periodic neurological dysfunction
versus progressive disease can not be determined.
In addition, the individuals in the fourth generation in
our family who were asymptomatic but had abnormal CAG
expansions are presumed to represent nonpenetrance due to
their young age.
In conclusion, SCA6 and EA2 are allelic disorders with a
phenotypic variability and we report on one Korean family
with EA2 and SCA6 caused by a CAG26 repeat expansion,
which is not reported yet in Korea.
Fig. 3. The distributions of CAG repeats in CACNA1A gene
obtained from the proband and his 12 family members. The
number of CAG repeat was 26 in this family.
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